These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9614617)

  • 41. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
    Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus.
    Ford-Adams ME; Murphy NP; Moore EJ; Edge JA; Ong KL; Watts AP; Acerini CL; Dunger DB
    Diabet Med; 2003 Aug; 20(8):656-60. PubMed ID: 12873294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin.
    Chico A; Saigi I; García-Patterson A; Santos MD; Adelantado JM; Ginovart G; de Leiva A; Corcoy R
    Diabetes Technol Ther; 2010 Dec; 12(12):937-45. PubMed ID: 21128840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.
    Jacobs MA; Keulen ET; Kanc K; Casteleijn S; Scheffer P; Devillé W; Heine RJ
    Diabetes Care; 1997 Aug; 20(8):1279-86. PubMed ID: 9250454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
    Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
    Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM
    Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
    Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
    Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections.
    Colombel A; Murat A; Krempf M; Kuchly-Anton B; Charbonnel B
    Diabet Med; 1999 Apr; 16(4):319-24. PubMed ID: 10220206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp).
    Wiefels K; Hübinger A; Dannehl K; Gries FA
    Horm Metab Res; 1995 Sep; 27(9):421-4. PubMed ID: 8557242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA; Zinman B; Campos RV; Strack T;
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction.
    Janssen MM; Snoek FJ; Masurel N; Hoogma RP; Devillé WL; Popp-Snijders C; Heine RJ
    Diabetes Care; 2000 May; 23(5):629-33. PubMed ID: 10834421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
    Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
    Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults : a real-life design.
    Stades AM; Hoekstra JB; van den Tweel I; Erkelens DW; Holleman F;
    Diabetes Care; 2002 Apr; 25(4):712-7. PubMed ID: 11919130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50.
    Gao Y; Li G; Li Y; Guo X; Yuan G; Gong Q; Yan L; Zheng Y; Zhang J
    Int J Clin Pract; 2008 Sep; 62(9):1344-51. PubMed ID: 18657196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.
    Bragd J; von Döbeln A; Lins PE; Adamson U; Bergström J; Oskarsson P
    Diabetes Technol Ther; 2010 Sep; 12(9):689-93. PubMed ID: 20687863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.